Table 2. Sites of relapse among patients... | American Society of Hematology

Table 2.

Sites of relapse among patients who were PET1⁻ or PET1⁺: no up-front RT vs up-front RT

Site of relapse	PET 1⁻, n = 119*		PET 1⁺, n = 103†
Site of relapse	No IFRT, n (%) n = 14	IFRT, n (%) n = 1	No IFRT, n (%) n = 16	IFRT, n (%) n = 10
Pet 1 (+) site‡	—	—	9 (56.3)	5 (50)
Initial site	11 (78)	1 (100)	—	—
PET 1 (+) and initial site‡	—	—	5 (31.3)	0 (0)
Initial site beyond PET1⁺ site‡	—	—	0 (0)	1 (10)
Initial and new site	3 (21)	0 (0)	2 (12.5)	2 (20)
New site only	0 (0)	0 (0)	0 (0)	2 (20)

Site of relapse	PET 1⁻, n = 119*		PET 1⁺, n = 103†
Site of relapse	No IFRT, n (%) n = 14	IFRT, n (%) n = 1	No IFRT, n (%) n = 16	IFRT, n (%) n = 10
Pet 1 (+) site‡	—	—	9 (56.3)	5 (50)
Initial site	11 (78)	1 (100)	—	—
PET 1 (+) and initial site‡	—	—	5 (31.3)	0 (0)
Initial site beyond PET1⁺ site‡	—	—	0 (0)	1 (10)
Initial and new site	3 (21)	0 (0)	2 (12.5)	2 (20)
New site only	0 (0)	0 (0)	0 (0)	2 (20)

PET1⁻ patients were considered RERs.

PET1⁺ patients were considered SERs.

Pertinent to PET1⁺ patients only.